- Trial Phase
- Phase 2
- Time to Market
- Unknown — development is paused. Even if a best-case partnership/partnership, the drug is years from approval. BioAtla's strategic review could result in a sale/partnering of the asset, but no timeline is set.
- Why 4/10
- No hard dated binary catalyst (PDUFA or pivotal readout is scheduled in the next ~12 months. Evalstotug's Phase 2 program is paused pending BioAtla's strategic alternatives process. The next catalyst is the outcome of that process (asset sale/partnership or bankruptcy — not a clinical/regulatory decision, making this a 4 on the 0-10 scale.</impactRationale> <｜DSML｜parameter name="upcomingCatalysts" string="false">["Outcome of BioAtla's strategic alternatives process (potential asset sale, partnership, or other transaction — no deadline set", "Potential Yorkville SEPA draws (dilution catalyst", "Q3 2026 earnings (Nov 11, 2026) — cash position update"]
Evalstotug's development is paused pending BioAtla's strategic alternatives process. The key event to watch is whether BioAtla can find a partner or buyer for evalstotug (or its other CAB assets) before cash runs out. With only $1.5M on hand and a $40M Yorkville SEPA that would cause ~490% dilution if fully drawn, the stock is a speculative bet on an asset sale — not on clinical data.
Price Chart
Executive Summary
Evalstotug (BA3071) is BioAtla's conditionally active anti-CTLA-4 antibody designed to reduce toxicity vs. standard CTLA-4 inhibitors by activating only in the acidic tumor microenvironment. Phase 1/2 data have been presented at ASCO 2024, SITC 2024, and AACR IO 2025, showing early promise in advanced solid tumors and melanoma. However, BioAtla is in severe financial distress — only $1.5M cash, delisted from Nasdaq to OTCQB, a 70% workforce reduction, and a formal strategic alternatives process that has paused clinical programs. The drug's future depends entirely on whether BioAtla can sell or partner the asset before running out of cash, making this a high-risk, binary situation for investors.
How It Works
Evalstotug is an antibody that blocks CTLA-4, a protein that acts like a 'brake' on the immune system's cancer-fighting T-cells. Unlike standard CTLA-4 blockers (like ipilimumab/Yervoy), evalstotug is designed to activate only in the acidic environment inside tumors, not in healthy tissue. This 'conditionally active' approach aims to reduce the severe side effects that limit how much of these drugs can be given, potentially allowing higher, more effective doses.
Trial Status
Evalstotug has completed Phase 1 dose-escalation in a Phase 1/2 study (NCT05180799) in advanced solid tumors, with Phase 1 data presented at ASCO 2024, updated Phase 1/early Phase 2 data at SITC 2024, and melanoma-specific results at AACR IO 2025 (Feb 2025). The Phase 2 expansion cohorts were ongoing but are now paused/delayed pending the outcome of BioAtla's formal strategic alternatives process.
The Two-Sided Case
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioAtla, Inc. S-1 BCAB ·Originating report